Interim assesment of the results of a clinical study of the regularities of changes in the patterns of lipid peroxidation -antioxidant defence in stomach cancer


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. Stomach cancer (SC) occupies a leading position in the structure of oncological morbidity and mortality. Violation of the regulation of the processes of lipid peroxidation (LP) - antioxidant defence (AOD) causes a decrease in the body’s resistance and contributes to the development and progression of diseases. Objective. Evaluation of the patterns of LP- AOD in SC. Methods. The parameters of the immune system and LP-AOD in chronic atrophic gastritis (CAG) and SC were evaluated for one year after the detection of pathology. The study included 50 patients with CAG and 50 patients with SC. The control group consisted of 85 healthy donors. The study material was venous blood, which was taken from patients upon admission before the start of the pathogenetic treatment. The study was conducted from June to September 2019, venous blood was taken from patients one time. LP-AOD indicators were determined by spectrophotometric methods. For testing statistical hypotheses, the critical level of significance was taken equal to p<0.05. Results. Compared to the control group, patients with SC has increased blood plasma malondialdehyde, catalase, glutathione-S-transferase, glutathione peroxidase, and ceruloplasmin levels, and prooxidant processes prevailed over antioxidant ones. The highest values of indicators were detected at stage III disease. Compared to patients with CAG, patients with SC had more pronounced increase in the malondialdehyde levels. A decrease in the activity of the superoxide dismutase enzyme indicates inhibition of the leading enzyme in the enzymatic link of AOD. An increase in ceruloplasmin protein proves its compensatory activation in oxidative stress. Conclusion. High malondialdehyde and ceruloplasmin levels, low activity of superoxide dismutase are pathogenetic mechanisms in the transformation of CAG into SC.

全文:

受限制的访问

作者简介

O. Smirnova

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences" “Research Institute of Medical Problems of the North"

Email: ovsmirnova71@mail.ru
MD, Head of the Laboratory of Clinical Pathophysiology, Research Institute of Medical Problems of the North 3G, Partizan Zheleznyaka Street, Krasnoyarsk 660022, Russian Federation

V. Tsukanov

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences" “Research Institute of Medical Problems of the North"

Krasnoyarsk, Russia

A. Modestov

Krasnoyarsk Regional Clinical Oncology Center n. a. A.I. Kryzhanovsky

Krasnoyarsk, Russia

A. Sinyakov

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences" “Research Institute of Medical Problems of the North"

Krasnoyarsk, Russia

O. Moskalenko

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences" “Research Institute of Medical Problems of the North"

Krasnoyarsk, Russia

N. Elmanova

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences" “Research Institute of Medical Problems of the North"

Krasnoyarsk, Russia

E. Ovcharenko

Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences" “Research Institute of Medical Problems of the North"

Krasnoyarsk, Russia

N. Titova

Siberian Federal University

Krasnoyarsk, Russia

参考

  1. Бордин Д.С., Машарова А.А., Хомерики С.Г Хронический гастрит: современный взгляд на старую проблему. Сучасна Гастроентеролопя. 2013;1(69):72-9
  2. Вернигородский С.В. Особенности структурных изменений слизистой оболочки желудка при хроническом гастрите у лиц разных возрастных групп. Клиническая и экспериментальная морфология. 2014;1(9):4-7
  3. Волкова Н.Н. Risk factors for the development of chronic atrophic gastritis (literature review). РМЖ. 2013;21(31):1617-20
  4. Лазебник Л.Б, Васильев Ю.В., Щербаков П.Л. и др. Helicobacter pylori: распространенность, диагностика, лечение. Экспериментальная и клиническая гастроэнтерология. 2010;2:3-7
  5. Смирнова О.В., Титова Н.М., Елманова Н.Г. Особенности прооксидантной и антиоксидантной системы у больных множественной миеломой в зависимости от стадии заболевания. Бюл. экспериментальной биологии и медицины. 2014;157(3):357-61.
  6. Смирнова О.В., Титова Н.М., Манчук В.Т., Елманова Н.Г. Особенности цитокиновой регуляции у больных механической желтухой различного генеза. Современные проблемы науки и образования. 2015;4:425
  7. Павлович И.М., Гордиенко А.В., Бацков С.С. и др. Влияние Helicobacterpylori на морфологическое состояние слизистой оболочки желудка при хроническом гастрите. Медикобиологические и социально-психологические проблемы безопасности в чрезвычайных ситуациях. 2013;2:32-5
  8. Скворцов В.В., Скворцова Е.М. Актуальные вопросы диагностики и лечения антрального гастрита типа. Поликлиника. 2012;1(1):1026
  9. Степанов Ю.М., Симонова Е.В. Повышение информативности эндоскопической диагностики предраковых изменений и рака желудка у больных с атрофическим гастритом. Гастроэнтерология. 2013;4(50):23-33
  10. Adamu M.A., Weck M.N., Rothenbacher D., et.al. Incidence and risk factors for the development of chronic atrophic gastritis: five year follow up of a population based cohort study Int J Cancer. 2011;128:1652-58. doi: 10.1002/ijc.25476.
  11. Alakkari A., Zullo A., O'Connor H.J. Helicobacter pylori and Nonmalignant Diseases. Helicobacter. 2011;16(1):33-7. doi: 10.1111/j.1523-5378.2011.00878.x.
  12. Correa P Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211-17. doi: 10.1016/j.gtc.2013.01.002.
  13. Dinis-Ribeiro M., Areia M., de Vries A., et ai. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathoiogy (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74-94. doi: 10.1055/s-0031-1291491.
  14. Graham D.Y Helicobacter pylori update: gastric cancer, reiiabie therapy, and possibie benefits. Gastroenterol. 2015;148(4):719-31. doi: 10.1053/j.gastro.2015.01.040.
  15. Hunt R.H., Xiao S.D., Megraud F, et ai. Heiicobacter Pyiori in deveioping countries. Worid Gastroenterology Organisation Giobai Guideline. J Gastrointestin Liver Dis. 2011;20(3):299-304. doi: 10.1097/MCG.0b013e31820fb8f6.
  16. Lee Y.C., Chen T.H., Chiu H.M., et ai. The benefit of mass eradication of Heiicobacter pyiori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676-82. doi: 10.1136/gutjni-2012-302240.
  17. Tonkic A., Tonkic M., Lehours P, et ai. Epidemioiogy and diagnosis of Heiicobacter pyiori infection. Heiicobacter. 2012;17(1):1-8. doi: 10.1111/j.1523-5378.2012.00975.x.
  18. Wang J., Xu L., Shi R., et ai. Gastric atrophy and intestinai metapiasia before and after Heiicobacter pyiori eradication: a metaanalysis. Digestion. 2011;83(4):253-60. doi: 10.1159/000280318.
  19. Watari J., Chen N., Amenta P.S., et ai. Heiicobacter pyiori associated chronic gastritis, ciinicai syndromes, precancerous iesions, and pathogenesis of gastric cancer deveiopment. World J Gastroenterol. 2014;20(18):5461-73. doi: 10.3748/wjg.v20.i18.5461.
  20. Yoshida T, et ai. Cancer deveiopment based on chronic active gastritis and resuiting gastric atrophy as assessed by serum ieveis of pepsinogen and Heiicobacter pyiori antibody titer. Int J Cancer. 2014;134(6):1445-57. doi: 10.1002/ijc.28470.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##